drugset / Trial / NCT07100925
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).
Timeline
- Start
- 2025-12-15
- Primary completion
- 2030-06
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tolododekin alfa | Protein / enzyme biologic | — | — |